TNSN07078A1 - HUMAN GROWTH HORMONE CONJUGATES WITH GLYCEROL BRANCHED POLYETHYLENE GLYCOL, PROCESS FOR THEIR PREPARATION AND METHODS FOR THEIR USE - Google Patents

HUMAN GROWTH HORMONE CONJUGATES WITH GLYCEROL BRANCHED POLYETHYLENE GLYCOL, PROCESS FOR THEIR PREPARATION AND METHODS FOR THEIR USE

Info

Publication number
TNSN07078A1
TNSN07078A1 TNP2007000078A TNSN07078A TNSN07078A1 TN SN07078 A1 TNSN07078 A1 TN SN07078A1 TN P2007000078 A TNP2007000078 A TN P2007000078A TN SN07078 A TNSN07078 A TN SN07078A TN SN07078 A1 TNSN07078 A1 TN SN07078A1
Authority
TN
Tunisia
Prior art keywords
leu
ser
glu
gln
phe
Prior art date
Application number
TNP2007000078A
Other languages
French (fr)
Inventor
Rory F Finn
Ned R Siegel
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708806&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN07078(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of TNSN07078A1 publication Critical patent/TNSN07078A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne la PEGylation de l'hormone de croissance humaine (hGH) en utilisant un PEG ramifié avec du glycérol. La présente invention concerne également des procédes pour la PEGylation de la hGH. En outre, la présente invention concerne des compositions pharmaceutiques comprenant la hGH PEGgylée. Une forme de réalisation supplémentaire consiste en l'utilisation de la hGH PEGylée pour le traitement de troubles de la croissance et du développement. Phe pro Thr Ile pro Ieu ser Arg lieu Phe Asp Asn12 Ala Met Leu Arg Ala Hil Arg leu His Gln leu Ala24 Phe Asp Thr Tyr Gln Glu Phe Glu Glu Ale Tyr Ile 36 Pro LYs Glu Gln Lys Tyr Ser Phe Leu Gln Asn Pro48 Gln thr SeI' Leu Cys phe Ser Glu Ser Ile Pro Thr60 Pro ser Afin Arg Glu Glu 'l'hr Gln Gln Lys Ser Asn72 Leu Glu Leu Leu Arg Ile Ser Leu Leu Leu Ile Gln84 Ser Trp Leu Glu Pro Val Gln Ser Leu Arg Ser Val96 Phe Ala Asn Ser Leu Val Tyr Gly Ala Ser Asp Ser108 Asn val Tyr Asp Leu Leu L,ys Asp Leu Glu Glu Gly120 Ile Gln Thr Leu Met Gly Arg Leu Glu Asp Gly Ser132 Pro Arg Thr Gly Gln Ile Phe Lys Gln Thr Tyr Ser 144 Lys Phe Asp Thr Asn Ser His Asn Asp Asp Ala Leu156 Leu Lys Asn Tyr Gly Leu Leu Tyr Cye Phe Arg Lys168 ASp Met Asp Lys val Glu Thr phe Leu Arg Ile Val180 Gln Cys Arg Ser Val Glu Gly ser Cys G1y Phe 191 SEQ ID NO:1The present invention relates to the PEGylation of human growth hormone (hGH) using a branched PEG with glycerol. The present invention also relates to methods for the PEGylation of hGH. In addition, the present invention relates to pharmaceutical compositions comprising PEGylated hGH. A further embodiment is the use of PEGylated hGH for the treatment of growth and developmental disorders. Phe pro Thr Pro pro Ieu ser Arg place Phe Asp Asn12 Ala Met Leu Arg Ala Hil Arg leu His Gln leu Ala24 Phe Asp Thr Tyr Tyr Gln Glu Phe Glu Glu Ale Tire Ile 36 Pro LYs Glu Gln Lys Tyr Ser Phe Gln Gln Asn Pro48 Gln thr SeI 'Leu Cys phe Ser Glu Ser Ile Pro Thr60 Pro ser Arg Glu Glu' hr Gln Gln Lys Ser Asn72 Leu Glu Leu Leu Arg Ile Ser Leu Leu Leu Ile Gln84 Ser Trp Leu Glu Pro Val Gln Ser Leu Arg Ser Val96 Phe Ala Asn Ser Leu Val Tyr Gly Ala Ser Asp Ser108 Asn val Tyr Asp Leu Leu L, ys Asp Leu Glu Glu Gly120 Ile Gln Thr Leu Met Gly Arg Leu Glu Asp Gly Ser132 Pro Arg Thr Gly Gln Ile Phe Lys Gln Thr Tyr Ser 144 Lys Phe Asp Thr Asn Ser His Asn Asp Asp Ala Leu156 Leu Lys Asn Tyr Gly Leu Leu Tyr Cye Phe Arg Lys168 ASp Met Asp Lys val Glu Thr phe Leu Arg Ile Val180 Gln Cys Arg Ser Val Glu Gly ser Cys G1y Phe 191 SEQ ID NO: 1

TNP2007000078A 2004-08-31 2007-02-27 HUMAN GROWTH HORMONE CONJUGATES WITH GLYCEROL BRANCHED POLYETHYLENE GLYCOL, PROCESS FOR THEIR PREPARATION AND METHODS FOR THEIR USE TNSN07078A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60594504P 2004-08-31 2004-08-31
PCT/IB2005/002939 WO2006024953A2 (en) 2004-08-31 2005-08-25 Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof

Publications (1)

Publication Number Publication Date
TNSN07078A1 true TNSN07078A1 (en) 2008-06-02

Family

ID=35708806

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000078A TNSN07078A1 (en) 2004-08-31 2007-02-27 HUMAN GROWTH HORMONE CONJUGATES WITH GLYCEROL BRANCHED POLYETHYLENE GLYCOL, PROCESS FOR THEIR PREPARATION AND METHODS FOR THEIR USE

Country Status (24)

Country Link
EP (1) EP1789092A2 (en)
JP (1) JP2008511610A (en)
KR (1) KR20070042567A (en)
CN (1) CN101010105A (en)
AP (1) AP2007003919A0 (en)
AR (1) AR050851A1 (en)
AU (1) AU2005278903A1 (en)
BR (1) BRPI0515118A (en)
CA (1) CA2577999A1 (en)
CR (1) CR8942A (en)
EA (1) EA200700380A1 (en)
EC (1) ECSP077281A (en)
GT (1) GT200500235A (en)
IL (1) IL181085A0 (en)
MA (1) MA28908B1 (en)
MX (1) MX2007002441A (en)
NL (1) NL1029828C2 (en)
NO (1) NO20071322L (en)
PE (1) PE20060654A1 (en)
TN (1) TNSN07078A1 (en)
TW (1) TW200621291A (en)
UY (1) UY29088A1 (en)
WO (1) WO2006024953A2 (en)
ZA (1) ZA200701802B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
BR9812267B1 (en) 1997-07-14 2013-11-26 Recombinant Growth Hormone.
EP1144613B2 (en) 1999-01-14 2020-05-06 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
MX2008014358A (en) * 2006-05-12 2008-11-24 Dong A Pharm Co Ltd Polyethylene glycol-interferon alpha conjugate.
JP2008069073A (en) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd Lactoferrin conjugate and its manufacturing method
KR101079993B1 (en) 2006-11-17 2011-11-04 동아제약주식회사 Polyethylene glycol-G-CSF conjugate
CL2008002399A1 (en) 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
WO2010011096A2 (en) * 2008-07-23 2010-01-28 Hanmi Pharmaceutical Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends
AU2009276458B2 (en) 2008-07-31 2014-06-19 Pharmaessentia Corp. Peptide-polymer conjugates
US8535655B2 (en) 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
PT2355853T (en) * 2008-10-10 2017-03-15 Polyactiva Pty Ltd Biodegradable polymer - bioactive moiety conjugates
SI2340271T1 (en) 2008-10-10 2019-08-30 Polyactiva Pty Ltd. Polymer-bioactive agent conjugates
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
JP6086528B2 (en) 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Growth hormone with long-term in vivo efficacy
CN101831067A (en) * 2010-05-31 2010-09-15 王二新 Polyethylene glycol ester conjugate and application thereof in medicine preparation
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
CN102367290B (en) * 2011-04-26 2013-05-08 厦门赛诺邦格生物科技有限公司 Chain-functionalized multi-level branched polyethylene glycol and synthesis method thereof
WO2014110867A1 (en) * 2013-01-17 2014-07-24 厦门赛诺邦格生物科技有限公司 Monofunctional branched polyethyleneglycol and bio-related substance modified by same
CN104877127B (en) 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 A kind of eight arms polyethyleneglycol derivative, preparation method and its bio-related substance of modification
SI3215193T1 (en) 2014-11-06 2024-02-29 Pharmaessentia Corporation Dosage regimen for pegylated interferon
JP7227633B2 (en) * 2017-12-29 2023-02-22 エフ． ホフマン－ラ ロシュ エージー． Methods for providing PEGylated protein compositions
EP3731872B1 (en) 2017-12-29 2021-11-24 F. Hoffmann-La Roche AG Process for providing pegylated protein composition
JP7137625B2 (en) * 2017-12-29 2022-09-14 エフ．ホフマン－ラ ロシュ アーゲー Methods for providing PEGylated protein compositions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
JP3092531B2 (en) * 1996-11-05 2000-09-25 日本油脂株式会社 Method for producing imidyl succinate-substituted polyoxyalkylene derivative
BR9812267B1 (en) * 1997-07-14 2013-11-26 Recombinant Growth Hormone.
JP3921781B2 (en) * 1998-02-12 2007-05-30 日本油脂株式会社 Carboxyl group-containing polyoxyalkylene compound
EP1144613B2 (en) * 1999-01-14 2020-05-06 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
IL162031A0 (en) * 2001-11-20 2005-11-20 Pharmacia Corp Chemically-modified human growth hormone conjugates
AP2005003246A0 (en) * 2002-09-09 2005-03-31 Nektar Therapeutics Al Corp Water-soluble polymer alkanals
JP4412461B2 (en) * 2002-11-20 2010-02-10 日油株式会社 Modified bio-related substance, production method thereof and intermediate
WO2004060406A2 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Polymeric reagents comprising a ketone or a related functional group
TR201907313T4 (en) * 2003-05-23 2019-06-21 Nektar Therapeutics PEG derivatives containing two PEG chains.

Also Published As

Publication number Publication date
ECSP077281A (en) 2007-03-29
MX2007002441A (en) 2007-05-04
IL181085A0 (en) 2007-07-04
EA200700380A1 (en) 2007-10-26
GT200500235A (en) 2006-03-21
ZA200701802B (en) 2008-08-27
NL1029828C2 (en) 2006-10-20
NL1029828A1 (en) 2006-03-01
WO2006024953A3 (en) 2007-01-18
JP2008511610A (en) 2008-04-17
CA2577999A1 (en) 2006-03-09
NO20071322L (en) 2007-05-29
KR20070042567A (en) 2007-04-23
EP1789092A2 (en) 2007-05-30
PE20060654A1 (en) 2006-08-12
MA28908B1 (en) 2007-10-01
BRPI0515118A (en) 2008-07-01
CR8942A (en) 2007-08-16
AP2007003919A0 (en) 2007-02-28
AU2005278903A1 (en) 2006-03-09
TW200621291A (en) 2006-07-01
CN101010105A (en) 2007-08-01
WO2006024953A2 (en) 2006-03-09
AR050851A1 (en) 2006-11-29
UY29088A1 (en) 2006-03-31

Similar Documents

Publication Publication Date Title
TNSN07078A1 (en) HUMAN GROWTH HORMONE CONJUGATES WITH GLYCEROL BRANCHED POLYETHYLENE GLYCOL, PROCESS FOR THEIR PREPARATION AND METHODS FOR THEIR USE
AU2017216533B2 (en) Improved peptide pharmaceuticals
ES2397852T3 (en) CGRP peptide antagonists and conjugates
US7381707B2 (en) Treatment of dry eye
AU2015289642A1 (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2014081872A1 (en) Improved peptide pharmaceuticals for insulin resistance
EP2710031A2 (en) Improved peptide pharmaceuticals for insulin resistance
US10494402B2 (en) Peptides that stimulate subcutaneous adipogenesis
EP2922877A1 (en) Improved peptide pharmaceuticals
EP1792915A3 (en) Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
AU2015266854A2 (en) Improved peptide pharmaceuticals for insulin resistance
Gourlet et al. Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors
FR2860236A1 (en) PEPTIDES HAVING PARTICULARLY ANTI-ANGIOGENIC ACTIVITY AND THERAPEUTIC APPLICATIONS THEREOF
US20180230188A1 (en) Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
CN103501801A (en) Parathyroid hormone analogs, compositions and uses thereof
Arsenijevic et al. Vasopressin-binding sites in the pig pituitary gland: competition by novel vasopressin antagonists suggests the existence of an unusual receptor subtype in the anterior lobe
YU48997A (en) Novel biologically active proteins, their pharmaceutical compositions and procedure for obtaining thereof
US9464128B2 (en) Site-specific pegylated linear salmon calcitonin analogues
Bai Subcellular distribution of proteolytic activities degrading bioactive peptides and analogues in the rat small intestinal and colonic enterocytes
HK1092162A1 (en) Biologically active peptides comprising isoleucyl-valyl-threonyl- asparaginyl-threonyl-threonine (ivtntt)
CN112654634B (en) Synthetic peptides, prodrugs, pharmaceutical compositions and uses
RU2820132C2 (en) Method for improving lower urinary tract symptoms
CA3139959A1 (en) Method of improving lower urinary tract symptoms
EP1307217A2 (en) Vip-related peptides for the treatment of skin disorders
TH95342A (en) Methastin derivatives and their use